Dr. Kaveh Vejdani, Co-founder and Chief Medical and Technology Officer at Darmiyan, discusses BrainSee, the first FDA-approved AI medical software designed to evaluate cognitive prognosis in patients with mild cognitive impairment (MCI).

With a background in nuclear medicine and expertise in medical image processing and machine learning, Dr. Vejdani's work reflects his commitment to innovation in healthcare. BrainSee aims to solve the global crisis of dementia through early detection and accurate prognosis of MCI, potentially improving patients' brain health journeys and treatment outcomes.

The BrainSee technology combines MRI data with cognitive assessments to predict the likelihood of progression to Alzheimer's disease, providing valuable support to both patients and healthcare providers in managing MCI.

00:00 Meet Dr. Kaveh Vejdani: An Innovator at the Intersection of AI and Healthcare

01:25 The Genesis of a Medical Visionary: From Passion to Innovation

02:30 Understanding Mild Cognitive Impairment (MCI) with Dr. Vejdani

07:10 The Revolutionary Brain See: A Leap Forward in Cognitive Health

11:22 Navigating the Complexities of MCI Diagnosis and Management

22:00 The Future of MCI Detection: Brain See's Impact and Potential

27:44 Final Thoughts: Empowering MCI Understanding and Management

Resources:

• Learn more about Darmyian on their website.

• Explore Brain See and its recent FDA approval!

• Read the 2024 Alzheimer’s Disease Facts & Figures report.